trending Market Intelligence /marketintelligence/en/news-insights/trending/fhlyAR_lX8wxUi0MogMLlg2 content esgSubNav
In This List

Pfizer Q2 income up YOY, revises earnings guidance

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Pfizer Q2 income up YOY, revises earnings guidance

Pfizer Inc. raised the midpoint of its full-year earnings guidance after reporting $4.10 billion, or 67 cents per share, in second-quarter adjusted income.

The result an increase from $3.93 billion, or 64 cents per share, in the second quarter of 2016 compares to the S&P Capital IQ normalized EPS consensus estimate of 66 cents.

The pharma major will now target full-year adjusted EPS of $2.54 to $2.60 as opposed to $2.50 to $2.60 previously. Pfizer's revenue guidance remains at between $52 billion and $54 billion.

The S&P Capital IQ normalized EPS estimate consensus for the year is $2.55.

Pfizer generated $12.90 billion in second quarter sales, down 2% year-over-year given the divestiture of Hospira Infusion Systems.

On a GAAP basis, the company booked a second-quarter income of $3.10 billion, or 51 cents per share, up from $2.05 billion, or 33 cents per share, in the same quarter of 2016.